Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke
von Kummer R, Mori E, Truelsen T, Jensen J, Grønning B, Fiebach J, Lovblad K, Pedraza S, Romero J, Chabriat H, Chang K, Dávalos A, Ford G, Grotta J, Kaste M, Schwamm L, Shuaib A, Albers G. Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke. Stroke 2016, 47: 2880-2887. PMID: 27803391, DOI: 10.1161/strokeaha.116.013715.Peer-Reviewed Original ResearchConceptsPlacebo-treated patientsSymptomatic intracranial hemorrhageSerious adverse eventsAdverse eventsMRS scoreTreatment armsIntracranial hemorrhagePooled analysisDay 90Major artery occlusionIschemic stroke patientsRankin Scale scoreMajor cerebral arteriesHigh-grade stenosisSignificant clinical benefitExtended time windowIntravenous desmoteplaseArterial recanalizationArtery occlusionIntravenous treatmentIschemic strokePrimary outcomeCerebral arteryRecanalization rateStroke patientsStroke Treatment Academic Industry Roundtable Recommendations for Individual Data Pooling Analyses in Stroke
Lees K, Khatri P, Alexandrov A, Bivard A, Boltze J, Broderick J, Campbell B, Creighton F, Fiorella D, Furlan A, Gorelick P, Hess D, Kim W, Latour L, Liebeskind D, Luby M, Lyden P, Lynch J, Marshall R, Menon B, Muir K, Palesch Y, Peng H, Pryor K, Mocco J, Rasmussen P, Sacco R, Schwamm L, Smith E, Solberg Y, Vagal A, Warach S, Wechsler L, Wintermark M, Yoo A, Zander K. Stroke Treatment Academic Industry Roundtable Recommendations for Individual Data Pooling Analyses in Stroke. Stroke 2016, 47: 2154-2159. PMID: 27406108, PMCID: PMC4961517, DOI: 10.1161/strokeaha.116.012966.Peer-Reviewed Original ResearchConceptsPooled analysisClinical implicationsClinical trial findingsIndividual patient dataPooled findingsPrespecified subgroupsOngoing trialsStroke trialsTrial findingsTreatment strategiesClinical careIndividual drugsPooling analysisTrial teamSuch drugsClass effectSevere disabilityTrial resultsPatient dataAnalysis planTrialsStatistical adjustmentTreatment effectsAcute Stroke Imaging Research Roadmap III Imaging Selection and Outcomes in Acute Stroke Reperfusion Clinical Trials
Warach S, Luby M, Albers G, Bammer R, Bivard A, Campbell B, Derdeyn C, Heit J, Khatri P, Lansberg M, Liebeskind D, Majoie C, Marks M, Menon B, Muir K, Parsons M, Vagal A, Yoo A, Alexandrov A, Baron J, Fiorella D, Furlan A, Puig J, Schellinger P, Wintermark M, Ansari S, Aviv R, Barreto A, Broderick J, Christensen S, Davis S, Demchuk A, Dippel D, Donnan G, Fiebach J, Fiehler J, Houser G, Grotta J, Hacke W, Hill M, Hsia A, Jovin T, Köhrmann M, Latour L, Leigh R, Lees K, Lev M, Marshall R, Mocco J, Nadareishvili Z, Nogueira R, Olivot J, Palesch Y, Pedraza S, Sasaki M, Saver J, Savitz S, Schwamm L, Simpkins A, Smith W, Thijs V, Thomalla G, Wechsler L, Wu O, Zaharchuk G, Zaidat O. Acute Stroke Imaging Research Roadmap III Imaging Selection and Outcomes in Acute Stroke Reperfusion Clinical Trials. Stroke 2016, 47: 1389-1398. PMID: 27073243, PMCID: PMC6058693, DOI: 10.1161/strokeaha.115.012364.Peer-Reviewed Original ResearchConceptsClinical trialsEndovascular trialsImaging Working GroupFinal infarct volumeLarge vessel occlusionProspective clinical trialsImaging sessionAmerican SocietyOptimal imaging methodInfarct volumeStroke neurologistsEndovascular treatmentPooled analysisTherapy clinical trialsVessel occlusionImaging selectionGood collateralsNeurovascular imagingConsensus recommendationsUS FoodDrug AdministrationNeurological disordersPooled dataTrialsNational Institute